News of the index components OMX Copenhagen 20

Index

OMXC20

DK0016268840

Market Closed - Nasdaq Copenhagen 16:05:00 03/07/2024 BST			5-day change	1st Jan Change
2,826 ^PTS	-1.46%		-2.92%	+23.77%

07-02	Indices: CAC relaxes, Merval soars
06-05	Nordic Shares Moved Upward Wednesday; Crayon Group Topped Leaders	DJ

News of the index components

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US FTC seeks more information on Novo Nordisk parent-Catalent deal NOVO B	05-03	RE
Transcript : Novo Nordisk A/S, Q1 2024 Earnings Call, May 03, 2024 NOVO B	05-03
Ventus Therapeutics, Inc. Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk NOVO B	05-03	CI
NOVO NORDISK : Buy rating from Deutsche Bank NOVO B	05-03	ZD
Trading in Pandora A/S Shares by Board Members, Executives and Associated Persons PNDORA	05-03	AQ
DANSKE BANK : Q1: fading NII momentum shadows good progress on targets achievement DANSKE	05-03
Orsted A/S : Notification of managers' transactions ORSTED	05-03	PU
Notification of managers’ transactions ORSTED	05-03	EQ
Notification of managers’ transactions ORSTED	05-03	AQ
MOLLER-MAERSK : Goldman Sachs reiterates its Neutral rating MAERSK B	05-03	ZD
Tranche Update on Danske Bank A/S's Equity Buyback Plan announced on February 2, 2024. DANSKE	05-03	CI
Danske Bank A/S : Insider transaction disclosure no. 46 DANSKE	05-03	PU
Danske Bank: net income up 9% in Q1 DANSKE	05-03	CF
Danske Bank A/S, transactions by persons discharging managerial responsibilities DANSKE	05-03	GL
Danske Bank Reiterates FY24 Outlook After 'Good' Q1 Performance DANSKE	05-03	MT
ORSTED : Q1 24: Consistent results, no bad news this time ORSTED	05-03
Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024 NSIS B	05-03
Danske Bank CEO: Expects net interest income to top in Q3 DANSKE	05-03	RE
NOVO NORDISK : JP Morgan gives a Buy rating NOVO B	05-03	ZD
Transcript : Danske Bank A/S, Q1 2024 Earnings Call, May 03, 2024 DANSKE	05-03
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration NSIS B	05-03	GL
Trading statement Q1 2024 NSIS B	05-03	GL
Novonesis Provides Sales Guidance for the Year 2024 NSIS B	05-03	CI
Danske Bank A/S : Indicators for assessing systemically important banks 2023 DANSKE	05-03	PU
Danske Bank A/S : Internal Capital Adequacy Assessment - Q1 2024 DANSKE	05-03	PU
Danske Bank A/S : Supervisory Diamond Q1 2024 DANSKE	05-03	PU
Danske Bank reports Q1 net profit in line with expectations DANSKE	05-03	RE
Good start to the year driven by robust customer activity across the business and strong credit quality in uncertain environment. Net profit of DKK 5.6 billion for the first quarter of 2024 DANSKE	05-03	GL
Danske Bank A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 DANSKE	05-03	CI
Danske Bank A/S Provides Earnings Guidance for the Year 2024 DANSKE	05-03	CI
Genmab Posts Q1 Net Profit Surge; Revenue Jumps GMAB	05-03	MT
Genmab A/S : Investor Presentation - May 2024 GMAB	05-02	PU
Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK NOVO B	05-02	MT
Weight-loss drug Wegovy available in Canada starting May 6 for people with obesity NOVO B	05-02	AQ
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance GMAB	05-02	MT
Novo Nordisk CEO: Demand for Wegovy outstrips supply NOVO B	05-02	MT
AP MOLLER-MAERSK : Low-end of the 2024 guidance revised upwards MAERSK B	05-02
NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions NOVO B	05-02
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024 GMAB	05-02
Vegfinans Innlandet AS - Successful placement of new NOK bond issue DANSKE	05-02	AQ